OAG
3.1.2020 10:02:03 CET | Business Wire | Press release
OAG , the world’s leading provider of travel data and insight, today released the results of the OAG Punctuality League 2020 , a comprehensive ranking of the world’s largest airlines and airports for on-time performance (OTP).
Aeroflot finished as the most punctual Mega Airline in Europe and second-most punctual mega in the world (OTP 86.30%). Five additional European carriers earned spots among the world’s Top 20 Mega Airlines, including Air France (7th ; OTP 79.92%), British Airways (14th ; OTP 76.18%), Lufthansa (15th ; OTP 73.96%) and easyJet (17th ; OTP 73.08%).
Jet2 (OTP 82.69%), the UK’s third-largest airline, ranked fifth among the Top 20 Low-Cost Carriers (LCCs) and finished 19th globally. Several other European carriers, including Iberia (11th ; OTP 84.06%), Siberia Airlines (12th ; OTP 83.88%) and Air Baltic (13th ; OTP 83.63%) also placed among the world’s most punctual airlines.
British Airways’ hub London Heathrow (LHR; OTP 75.27%) ranked 13th among Mega Airports—a notable accomplishment for the world’s most internationally connected airport .
“The global market is reaching near peak OTP,” said John Grant, senior analyst with OAG. “The rise in performance is led by Mega Airlines like Aeroflot, Delta and Air France, which are simultaneously expanding the number of operated flights and maintaining high OTP. We’re seeing success trickle down to the hubs they service, which benefits the entire travel ecosystem.”
Delta (OTP 83.56%) ranked as the No. 1 Mega Airline in the continental U.S. for a third-straight year. Atlanta Hartsfield-Jackson (4th , ATL; OTP 83.74%) led the list of Delta hubs placing among the world’s most on-time Mega Airports. The top three Mega Airports in the world were Moscow Sheremetyevo (SVO; OTP 86.87%), Tokyo Haneda (HND; OTP 86.60%), and Singapore Changi (SIN; OTP 84.03%). Los Angeles International (LAX; OTP 79.62%) and New York’s John F. Kennedy (JFK; OTP 77.87%) ranked 7th and 8th , respectively.
Download the full report for more insights from OAG’s Punctuality League 2020 .
About OAG
OAG is a leading global travel data provider, that has been powering the growth and innovation of the air travel ecosystem since 1929. OAG has global operations in the UK, USA, Singapore, Japan, Lithuania and China.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200103005026/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
WHOOP Expands Commitment to Women's Health by Including One-Year Subscription of Natural Cycles° App in Membership4.8.2026 11:00:00 CEST | Press release
The integration gives eligible WHOOP members seamless access to the only FDA-cleared hormone-free birth control app, with the first year of Natural Cycles° included for those new to the app as part of their WHOOP membership. WHOOP, the human performance company, today announced an expansion of its women’s health offering through an integration with Natural Cycles° (NC°), the only FDA-cleared, hormone-free birth control app. WHOOP is offering a 12-month subscription to the NC° app to eligible new Natural Cycles users. Members with compatible WHOOP devices can now automatically share overnight skin temperature with the NC° app to enable personalized fertility insights and hormone-free birth control. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260804399367/en/ WHOOP Expands Commitment to Women's Health by Including One-Year Subscription of Natural Cycles° App in Membership The Natural Cycles app, a Class II medical device, u
Alphatax Makes Two Acquisitions to Strengthen Transfer Pricing Capabilities4.8.2026 10:00:00 CEST | Press release
Acquisitions Expand Transfer Pricing Offering and Support Long-Term Platform Strategy Alphatax, the global tax compliance software provider, has today announced the acquisitions of TP Accurate and Intra Pricing Solutions, expanding its transfer pricing capabilities and reinforcing its ambition to build the world's first tax operating system. The acquisitions strengthen Alphatax's transfer pricing portfolio with complementary capabilities across financial transactions and documentation. TP Accurate provides specialist software for intra-group financing arrangements, while Intra Pricing Solutions' flagship product, TPGenie, enables multinational organisations and advisors to produce transfer pricing documentation using intelligent automation and AI. Together, they expand Alphatax's ability to support the full transfer pricing lifecycle, helping customers manage compliance more efficiently while improving governance and reducing audit risk. They also represent another step towards Alphata
LabPMM® Launches Global KMT2A MRD Testing Service to Support Menin Inhibitor Development and Acute Leukemia Care4.8.2026 09:10:00 CEST | Press release
LabPMM®, an Invivoscribe® subsidiary, today announced the global availability of its new KMT2A measurable residual disease (MRD) testing service. The highly sensitive digital PCR service is available to healthcare providers, clinical researchers, and biopharmaceutical partners through LabPMM’s global laboratory network, with CAP/CLIA-accredited testing available in the U.S. The service addresses a growing need for accurate molecular monitoring in acute leukemias.1,2,3 KMT2A rearrangements (KMT2Ar) are oncogenic drivers in acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL).4 These rearrangements are present in about 80% of infant cases and 5-15% of childhood and adult leukemia cases.5 KMT2Ar leukemias are associated with chemotherapy resistance, high relapse rates, and poor clinical outcomes.5 The emergence of menin inhibitors is transforming the therapeutic landscape for patients with AML and ALL, particularly those with KMT2A-rearranged and NPM1-mutated disease.6 The
“HATSUNE MIKU LIGHTS TOKYO” Debuts on July 254.8.2026 09:00:00 CEST | Press release
Giant Hatsune Miku Returns to Light Up Tokyo’s Night! The Tokyo Metropolitan Government has been presenting year-round projection mapping displays on the Tokyo Metropolitan Government Building, using light and sound to showcase a wide range of artistic expressions as part of its efforts to create new nighttime tourism attractions in Tokyo. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260802298570/en/ © Crypton Future Media, INC. On Saturday, July 25, "HATSUNE MIKU LIGHTS TOKYO", featuring the globally beloved virtual singer Hatsune Miku, held its first screening. The work brings the world of the popular song “M@GICAL☆CURE! LOVE ♥ SHOT!” to life across the entire façade of the Tokyo Metropolitan Government Building. Since its launch in February 2024, “TOKYO Night & Light” has welcomed visitors from Japan and around the world, with total attendance surpassing 1.55 million. As one of Tokyo’s emerging landmark attractions, the
Mosaic Therapeutics appoints Dr Allison Jeynes as Chair of the Board4.8.2026 09:00:00 CEST | Press release
Accomplished life sciences leader with a proven track record of driving successful development of novel therapeutics, joins Mosaic to guide its next phase of growthAllison brings three decades of drug development, board and executive leadership experience to support Mosaic’s transition towards a clinical-stage company Mosaic Therapeutics, Ltd, (‘Mosaic’, or ‘the Company’) an oncology therapeutics company developing novel, targeted drug combinations across a range of haematological and solid cancers, today announced the appointment of Dr Allison Jeynes as Chair of the Board to support its next phase of growth and advancement towards clinical development. Allison succeeds Dr Edward Hodgkin, who remains a Non-Executive Director of the Board. Allison is a UK-trained oncologist and highly-experienced life sciences leader, and brings over three decades of drug development and executive experience to Mosaic Therapeutics. As CEO of Avillion, a clinical development company, for the last 13 year
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom